Home
Home

Osiris

Athersys Has Some Promise, But Controversy And Doubt Remain

Athersys Has Some Promise, But Controversy And Doubt Remain
Seeking Alpha

Investing In The Stem Cell Sector: An Overview

Investing In The Stem Cell Sector: An Overview
Seeking Alpha

The Vatican / NeoStem Partnership Looks To Create Interest And Advance Cell Therapy

The Vatican / NeoStem Partnership Looks To Create Interest And Advance Cell Therapy
Seeking Alpha

Stem Cell Therapy Companies: Underappreciated Outperformers

Stem Cell Therapy Companies: Underappreciated Outperformers
Seeking Alpha

10 Biotech Stocks With A History Of Beating Earning Expectations

10 Biotech Stocks With A History Of Beating Earning Expectations
TheStreet.com

The Stem Cell Sector Further Validates Itself With A Successful Q3

The Stem Cell Sector Further Validates Itself With A Successful Q3
Seeking Alpha

NeoStem To Create Value With Billion Dollar Potential

NeoStem To Create Value With Billion Dollar Potential
Seeking Alpha

Pluristem Standardizes Stem Cell Therapy, Opening Door To The Future Of Medicine

Pluristem Standardizes Stem Cell Therapy, Opening Door To The Future Of Medicine
Seeking Alpha

Nobel Prize Validates Recent Stem Cell Headlines

Nobel Prize Validates Recent Stem Cell Headlines
Seeking Alpha

The Promising, Cheap, And Growing Cell Therapy Arena Continues To Outperform The Market

The Promising, Cheap, And Growing Cell Therapy Arena Continues To Outperform The Market
Seeking Alpha